Literature DB >> 19228640

Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome).

Akiko Miyagi Maeshima1, Hirokazu Taniguchi, Junko Nomoto, Dai Maruyama, Sung-Won Kim, Takashi Watanabe, Yukio Kobayashi, Kensei Tobinai, Yoshihiro Matsuno.   

Abstract

Few cases of secondary CD5+ diffuse large B-cell lymphoma (DLBCL) that are not Richter syndrome have been reported previously. We report 9 cases of non-Richter syndrome secondary CD5+ DLBCL. Among 529 cases of DLBCL, 38 (7.2%) were CD5+ DLBCL, including 9 of secondary CD5+ DLBCL. Five cases gained CD5 expression during the clinical course of DLBCL (group 1). Three cases showed transformation from CD5- low-grade B-cell lymphoma to CD5+ DLBCL (group 2). The remaining case showed coexistence of CD5+ DLBCL and CD5+ follicular lymphoma. The clonal relationships of CD5- and CD5+ tumors were confirmed in all 4 available cases. Cases of secondary CD5+ DLBCL that were not Richter syndrome were classifiable into 3 groups. Groups 1 and 2 showed the gain of CD5 during the clinical course or transformation of the tumors, suggesting that CD5 expression is closely associated with the progression of B-cell lymphoma.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19228640     DOI： 10.1309/AJCP58FETFGLCKKW

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


  6 in total

1.  Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma.

Authors:  Hiroyuki Momota; Yoshitaka Narita; Akiko M Maeshima; Yasuji Miyakita; Aya Shinomiya; Takashi Maruyama; Yoshihiro Muragaki; Soichiro Shibui
Journal:  J Neurooncol       Date:  2009-12-13       Impact factor: 4.130

2.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

3.  Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.

Authors:  Naoko Tsuyama; Daisuke Ennishi; Masahiro Yokoyama; Satoko Baba; Reimi Asaka; Yuko Mishima; Yasuhito Terui; Kiyohiko Hatake; Kengo Takeuchi
Journal:  Oncotarget       Date:  2017-05-16

4.  Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.

Authors:  Hee Young Na; Ji-Young Choe; Sun Ah Shin; Hyun-Jung Kim; Jae Ho Han; Hee Kyung Kim; So Hee Oh; Ji Eun Kim
Journal:  PLoS One       Date:  2019-10-23       Impact factor: 3.240

5.  CD 5+ Peripheral B Cell Lymphoma With Transformation to CD 5+ Diffuse Large B Cell Lymphoma in the CNS: A Case Report Treated With Rituximab, High Dose Methotrexate, Cytarabine, and Intrathecal Methotrexate.

Authors:  Dariusz Uczkowski; Emmanuel Apor
Journal:  Cureus       Date:  2022-07-24

6.  Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.

Authors:  Xiao-Bo Ma; Yan-Ping Zhong; Yan Zheng; Jing Jiang; Yin-Ping Wang
Journal:  Cancer Med       Date:  2018-07-17       Impact factor: 4.452
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.